# A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC

> **NCT05212922** · PHASE2 · WITHDRAWN · sponsor: **Eucure (Beijing) Biopharma Co., Ltd**

## Conditions studied

- HCC
- NSCLC Stage IIIB
- NSCLC Stage IV

## Interventions

- **DRUG:** YH001 + Toripalimab

## Key facts

- **NCT ID:** NCT05212922
- **Lead sponsor:** Eucure (Beijing) Biopharma Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-06
- **Primary completion:** 2024-12
- **Final completion:** 2025-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor Decision
- **Last updated:** 2023-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05212922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05212922, "A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05212922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*